OBSEF

ObsEva SA

OBSEF, USA

ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

https://www.obseva.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
OBSEF
stock
OBSEF

ObsEva winds down and lays off all staff as money, options run out Fierce Biotech

Read more →
OBSEF
stock
OBSEF

ObsEva to delist from Nasdaq next week with eye on consolidating Swiss ops Seeking Alpha

Read more →

Finn Analysis

(Last Updated 2022-12-31)

Health Score

Return on Equity (ROE)

-

Very High

315.65 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very High

161.85 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

40.34 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

0.95

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of ObsEva SA

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2023-03-31

EPS Actual

0.3349

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2022-12-31)

Deep Value
Strong Deep Value(10)
Defensive
Moderately Defensive(3.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.5)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(3.5)
Momentum
No Momentum(0.5)
Net Net
Strong Net-Net(9.5)
Quality
High Quality(9)
Value
Undervalued(10)

Income Statement

(Last Updated 2022-12-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2022-12-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2022-12-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.